Connect with us

Digital Health

ConcertAI’s TeraRecon Adds the Releases of an AI-Assisted Clinical Suite Solution, Neuro Suite to Provide Comprehensive Solutions for Neurological Disorders

ConcertAI’s TeraRecon, the advanced visualization and clinical AI SaaS category leader, has announced the release of its AI-driven clinical suite, Neuro…

Published

on

This article was originally published by AITHORITY
ConcertAI's TeraRecon Adds the Releases of an AI-Assisted Clinical Suite Solution, Neuro Suite to Provide Comprehensive Solutions for Neurological Disorders

ConcertAI’s TeraRecon, the advanced visualization and clinical AI SaaS category leader, has announced the release of its AI-driven clinical suite, Neuro Suite. Purpose-built for disease triage, differential diagnostic insights, and care activation in many neurological disease states such as neuro-oncology, dementia, multiple sclerosis, and more, the Neuro Suite is designed to integrate across the entire healthcare organization and address challenges that clinicians face when making decisions regarding chronic neurological care.

Latest Insights: AiThority Interview with Luke Damian, Chief Growth Officer for Applause

“As an AI-assisted specialty clinical suite solution, Neuro Suite was created to enhance specialists’ ability to assess neurological diseases using various types of imaging modalities,” said Jeff Elton, Ph.D., CEO of ConcertAI. He further noted that, “ConcertAI’s TeraRecon Eureka Clinical AI offers a portfolio of solutions from the AI leaders in the neurology field, including Combinostics, Imaging Biometrics, and Cercare, creating a first-in-class capability and the only open AI architecture for Clinical AI.”

Combinostics’ algorithm provides a high-quality brain segmentation assessment on MRI images to assess atrophy and provides detailed reports, as well as other functionality, to aid in the probability of a diagnosis and differential diagnoses for degenerative cerebral pathologies such as dementia and Alzheimer’s disease. Imaging Biometric’s flagship algorithm provides meaningful insights into the oxygenation and blood supply of brain tumors, enabling key information regarding active tumor areas for assistance in diagnosis, progression, treatment, and post treatment outcomes and planning. Cercare’s proprietary perfusion technology provides unique insights into blood flow and cerebral blood volume for assessment of neurovascular function down to the capillary level, providing valuable insights into all cerebrovascular and neuroncology diseases. The strength of the Neuro Suite provides customers the flexibility to choose the algorithms that fit the specific needs of the neuro workflows within their hospitals.

Latest Insights: AiThority Interview with Vova Kyrychenko, CTO at Xenoss

“We are proud to enhance our neurological offerings beyond TR Neuro to an entire Neuro Suite, extending to our clinician customers an amazing array of tools streamlined into one place and able to be interacted with to help identify and treat critical neurological issues,” said TeraRecon’s President, Dan McSweeney.

ConcertAI is the leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies.

Latest Insights: AiThority Interview with Ahmad Al Khatib, CEO and Founder at Qudo

[To share your insights with us, please write to sghosh@martechseries.com]

The post ConcertAI’s TeraRecon Adds the Releases of an AI-Assisted Clinical Suite Solution, Neuro Suite to Provide Comprehensive Solutions for Neurological Disorders appeared first on AiThority.



Digital Health

Keep it Short

By KIM BELLARD OK, I admit it: I’m on Facebook. I still use Twitter – whoops, I mean X. I have an Instagram account but don’t think I’ve ever posted….

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading
Digital Health

Seattle startup Olamedi building platform to automate health clinic communications

A new Seattle startup led by co-founders with experience in health tech is aiming to automate communication processes for healthcare clinics with its software…

Continue Reading

Trending